# US 6,730,692 B2 · Treatment and prevention of reactive oxygen metabolite-mediated cellular damage

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,692 B2
- Document ID: US6730692B2
- Status: Granted
- Kind: B2
- Application number: 10/171,018
- Filed: 2002-06-11
- Published: 2002-10-17
- Granted: 2004-05-04
- Earliest claimed: 1999-01-08
- Assignees: Maxim Pharmaceuticals, Inc.
- Inventors: Kristoffer Hellstrand; Svante Hermodsson; Kurt R. Gehlsen
- Web page: https://patentgrep.com/patent/US6730692B2

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/33: Heterocyclic compounds
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/417: Imidazole-alkylamines, e.g. histamine, phentolamine
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/14: for RNA viruses
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 39/00: General protective or antinoxious agents
- A61P 39/06: Free radical scavengers or antioxidants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a method for preventing and/or reducing cellular and tissue damage caused by reactive oxygen metabolites (ROMs) released by phagocytic or endothelial cells in response to various disease states or pathologies. The methods of the present invention are useful in preventing and treating a variety of disease states or pathological situations in which ROMs are produced and released. The methods of the present invention contemplate reducing ROM-mediated damage by reducing the production and release of ROMs.

## Claims

### Claim 1

A method for treating a subject suffering from radiation injury comprising:
identifying a subject presenting the symptoms of radiation injury caused or exacerbated by the release of reactive oxygen metabolites (“ROMs”) from phagocytic cells resulting in ROM-mediated oxidative damage; and
administering a compound effective to inhibit the production or release of the ROMs, wherein the ROM production or release compound is selected from the group consisting of histamine, and histamine dihydrochloride.

### Claim 2 (depends on 1)

The method of claim 1, further comprising the step of administering an effective amount of a ROM scavenger.

### Claim 3 (depends on 2)

The method of claim 2, wherein the ROM scavenger is selected from the group consisting of catalase, glutathione peroxidase, ascorbate peroxidase, superoxide dismutase, vitamin A, vitamin E, and vitamin C.

### Claim 4 (depends on 2)

The method of claim 2, wherein the administration of the compound is accomplished by a method selected from the group consisting of injection, intramuscular injection, intravenous injection, implantation infusion device, inhalation, and transdermal diffusion.

### Claim 5 (depends on 1)

The method of claim 1, wherein the administration of the compound is accomplished by a method selected from the group consisting of intramuscular injection, intravenous injection, implantation infusion device, inhalation, and transdermal diffusion.

### Claim 6 (depends on 1)

The method of claim 1, further comprising administering a compound selected from the group consisting of IL-3, a retinoid, an allergen, a 5HT agonist, serotonin, and diphenyleneiodonium.

### Claim 7

A drug administration method comprising:
identifying a subject present the symptoms of radiation injury caused or or exacerbated by the release of a reactive oxygen metabolites (“ROMs”) from phagocytic cells resulting in ROM-mediated oxidative damage;
loading an infusion device with a compound effective to inhibit the production or release of ROMs; and
administering a compound effective to inhibit the production or release of the ROMs, wherein the ROM production or release compound is selected from the group consisting of histamine, histamine phosphate, and histamine dihydrochloride.

### Claim 8 (depends on 7)

The method of claim 7, further comprising administering an effective amount of a ROM scavenger.

### Claim 9 (depends on 8)

The method of claim 8, wherein the ROM scavenger is selected from the group consisting of catalase, glutathione peroxidase, ascorbate peroxidase, superoxide dismutase, vitamin A, vitamin E, and vitamin C.

### Claim 10 (depends on 8)

The method of claim 8, wherein the administration of the ROM scavenger is accomplished by a method selected from the group consisting of intramuscular injection, intravenous injection, implantation infusion device, inhalation, and transdermal diffusion.

### Claim 11 (depends on 7)

The method of claim 7, wherein the administration of the compound is accomplished by a method selected from the group consisting of injection, intramuscular injection, intravenous injection, implantation infusion device, inhalation, and transdermal diffusion.

### Claim 12 (depends on 7)

The method of claim 7, further comprising administering a compound selected from the group consisting of IL-3, a retinoid, an allergen, a 5HT agonist, serotonin, and diphenyleneiodonium.

### Claim 13 (depends on 7)

The method of claim 7 wherein said infusion device is a minipump.
